In combination with cisplatin-based chemotherapy, ONYX-015 has shown additive or potentially synergistic efficacy in vitro and in human tumour xenograft model studies in p53-deficient as well as in p53-functional tumour cells (Heise et al, 1997). This evidence concerns the gene TP53 and neoplasm.